Roxadustat cuts risk of congestive heart failure in patients with ESKD
Click Here to Manage Email Alerts
Patients who underwent dialysis and were prescribed roxadustat had a 27% reduction in risk for hospitalization for congestive heart failure compared with patients who took epoetin alfa, according to a study.
“[Congestive heart failure] CHF is associated with a poorer prognosis in [chronic kidney disease] CKD patients, with a prevalence that increases with CKD severity; approximately 20% in mild CKD (> 65 years) to 40% in patients on hemodialysis,” Robert Provenzano, MD, and colleagues wrote in an abstract presented at ASN Kidney Week.
Researchers reviewed data from phase 3 studies that compared roxadustat with placebo in patients with stage 3 to 5 CKD and with epoetin alfa in prevalent patients with end-stage kidney disease on dialysis. Data from a subgroup of patients on dialysis for 4 months or less were also reviewed.
In the pooled studies, 1,940 patients on dialysis received roxadustat and 1,940 patients received epoetin alfa. The baseline history of CHF in both arms was comparable between roxadustat (25.7%) and epoetin alfa (25.3%).
Results showed patients on dialysis who received roxadustat had a 27% reduction in risk for CHF hospitalization compared with patients who received epoetin alfa. Researchers also reported a trend toward reduction of risk compared with placebo in patients with CKD who were not on dialysis and compared with epoetin alfa in patients starting dialysis. Provenzano said the trend was not significant.
Collapse
Provenzano R, et al. Paper SA-OR39. Presented at: ASN Kidney Week. Oct. 22-25, 2020 (virtual meeting).
Read more about
Click Here to Manage Email Alerts